Category: Prohost Letters
The NEW Prohost Portfolio for 2019
The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes in our portfolio. Each table represents a sector among the various technological divisions that create more effective products currently being used, or intended to...
Read More
January 3, 2019
0
The Year in Review Part 1
Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN AWESOME YEAR for the biotech sector regarding its accomplishments. Many of the accomplished programs were unheard of regarding the degree of their positive impact...
Read More
December 31, 2017
0
Prohost Letter #415
Prohost Letter #415 New Promising Technologies PROTAC - A Technology That Offers a Superior Class of Drugs PROTAC is an approach that created a new class of drugs described as superior and far less toxic than targeted drugs known to...
Read More
December 3, 2017
0
End of the Year Decisions ~ Part 1
Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this Prohost Letter a guideline of our opinion regarding all the firms we picked for the Prohost Portfolio, rather than the few firms that we...
Read More
January 15, 2019
0
The Value of the Biotech Companies
Prohost Letter #434 Special Issue The Value of the Biotech Companies With a strong economy and an unemployment rate reaching the lowest percentage in decades we are witnessing strange, if not bizarre, market performance since the beginning of 2019. From...
Read More
August 12, 2019
0
End of the Year Decisions Part 2
Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected volatility in the stock market, we carefully reassessed each and very stock we picked for the Prohost Portfolio. Consequently, we had to change...
Read More
January 24, 2019
0
Now You See It, Now You Don't
Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be displayed or concealed depending on the news announcers’ or bloggers’ self-interests. The following contains cases of deliberate or unintentional omission of facts that led...
Read More
January 28, 2019
0
The Bizarre Market
The Week in Review #41 We Are Still Witnessing … The bizarre market performance that started in early 2019: In the past couple of months the great enthusiasm and response of the market to the undeniably strong economic indicators and...
Read More
August 20, 2019
0
End of the Year Decisions ~ Part 3
Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this series we selected two firms, both were recently added to the Prohost Portfolio . The first firm, FortySeven (FTSV) , focuses on an immunotherapy...
Read More
February 10, 2019
0
A Wild Wild Week
The Week in Review #17 A Wild Wild Week - The stock market looked as if it rejected all analysts’ opinions about the stocks they believed were “undervalued” and adopted only their opinion on what they believed are overvalued. As...
Read More
February 12, 2018
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)